A call to action to advance patient‐focused and decentralized clinical trials

R. Donald Harvey,Therica M. Miller,Patricia A. Hurley,Ramya Thota,Lora J. Black,Suanna S. Bruinooge,Leigh M. Boehmer,Mark E. Fleury,Jasmine Kamboj,Mujahid A. Rizvi,Banu E. Symington,William D. Tap,David M. Waterhouse,Laura A. Levit,Janette K. Merrill,Sheila A. Prindiville,Teri Pollastro,Jamie R. Brewer,Leslie P. Byatt,Leila Hamroun,Edward S. Kim,Nicole Holland,Grzegorz S. Nowakowski
DOI: https://doi.org/10.1002/cncr.35145
IF: 6.9209
2024-01-11
Cancer
Abstract:This commentary is a call to action for a concerted commitment and effort to transform clinical trials and enable people with cancer to participate in clinical trials closer to home. Three key strategies are identified to address major barriers: confront challenges with the interpretation of US Food and Drug Administration Form 1572 requirements (Statement of Investigator); broaden acceptance of local laboratories and imaging centers; and invest in the creation of effective, sustainable partnerships between research centers and local providers.
oncology
What problem does this paper attempt to address?